Th17 expansion in granulomatosis with polyangiitis (Wegener's): the role of disease activity, immune regulation and therapy

Table 2 Characteristics of patients with active disease at the time of sampling

Patient number	Age (years)	ANCA type	Disease duration (months)	Disease activity at time of sampling	BVAS	CRP (mg/L)
1	55	PR3	0	A, ENT, K, L	25	292
2	37	PR3	44	A, ENT	5	20
3	55	PR3	57	A, K, L	15	247
4	58	MPO	120	A, L	7	23
5	49	PR3	190	A, ENT, L	10	46
6	57	PR3	259	Ey, ENT	6	< 5
7	56	PR3	191	Ey	6	< 5
8	82	MPO	0	L	4	44
9	53	PR3	0	A, ENT, K, L	17	160
10	74	PR3	0	K	10	NA
11	69	PR3	9	ENT, K	14	211
12	41	MPO	0	A, ENT, K, S	17	44
13	58	MPO	0	ENT, K, S	14	116
14	70	MPO	0	A, ENT, K, L	19	188
15	53	PR3	15	Ey, K	12	12
16	24	PR3	9	A, Ey	3	16
17	40	MPO	33	ENT	6	< 5
18	41	MPO	284	K, L	12	< 5

None of the patients received induction therapy at the time of sampling. PR3/MPO, proteinase-3/myeloperoxidase; this reflects anti-neutrophil-cytoplasmic antibodies specificity (ANCA) at the time of diagnosis. Organ involvement of patients with active disease at the time of sampling is depicted. A, arthritis (joints); BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; ENT, ear-nose-throat; Ey, ophthalmologic manifestation of disease; K, kidney; L, lung; S, skin.

ISSN: 1478-6362